The United States veterinary vaccines market is expected to register a CAGR of 6.91% during the forecast period, 2022-2028, and is estimated to reach a revenue of $4063.99 million by 2028.

UNITED STATES VETERINARY VACCINES MARKET FORECAST 2022-2028

United States Veterinary Vaccines Market by Animal Type (Livestock Animal, Companion Animal, Aquaculture) Market by Product Type (Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Conjugate Vaccines, DNA Vaccines, Recombinant Vaccines, Subunit Vaccines) Market by Disease Type (Canine Disease, Porcine Disease, Bovine Disease, Poultry Disease, Aquaculture Disease, Other Diseases)

Request free sample

Report Summary

In general, livestock diseases contribute to varied problems in the livestock production systems, like income loss, food security uncertainties, and productivity losses. Thus, livestock disease management can minimize diseases and their spread, particularly by vaccinating animals. FMD (Foot-and-mouth disease) is highly contagious among cloven-hoofed animals like goats, sheep, swine, cattle, etc. As a result, the growing incidences of livestock diseases are a major growth driver.

To know more about this report, request a free sample copy

In the United States, the Center for Veterinary Biologics (CVB) regulates veterinary vaccines. The CVB grants product and establishment licenses to animal health companies for the manufacture and sale of veterinary biologics. Also, the advancements in vaccine development include developing non-replicating recombinant antigen vaccines, live-gene-deleted vaccines, live vector vaccines, nucleic acid-mediated vaccines, and live vector vaccines. For instance, Zoetis introduced a vectored recombinant vaccine in its poultry vaccine portfolio for protection against Marek’s and Newcastle disease viruses.

In addition, the vaccination in wildlife and companion animals for zoonotic diseases showed promising results. Also, the increasing awareness about disease prevention and technological advancements offers growth opportunities. Moreover, as per the November 2021 survey by the AVMA (American Veterinary Medical Association), cat and dog populations have increased in recent years.

Furthermore, several initiatives undertaken by the animal care organizations and the government are facilitating improvement in animal healthcare. For instance, the National Center Animal Health Emergency Management (AHEM) overlooks the affordability, safety, and good quality of products obtained from animals. Additionally, such organizations prioritize infections prevention caused by pathogenic agents. Such aspects make the US a conducive market for veterinary vaccines.

The segmentation assessment of the United States veterinary vaccines market entails the analysis of product type, disease type, and animal type. The product type is sub-segmented into conjugate vaccines, subunit vaccines, DNA vaccines, inactivated vaccines, toxoid vaccines, recombinant vaccines, and attenuated vaccines.

Recombinant vaccine production uses recombinant DNA technology. These vaccines are made using yeast or bacterial cells for vaccine manufacturing. A small piece of DNA is taken from the bacterium or virus and inserted into manufacturing cells. This entails DNA encoding an antigen insertion that enables an immune response into mammalian or bacterial cells, expressing the antigen in these cells before purifying it from them. One of the prominent examples of a recombinant vaccine is NUPLURA® PH+. It protects cattle from herd diseases.

Some of the leading market players include Zoetis, Elanco Animal Health, Merck Animal Health, Phibro Animal Health, Neogen, etc.

Phibro Animal Health Corporation is a globally diversified mineral nutrition and animal health company. It markets, manufactures, and develops a vast range of products for food animals that include dairy cattle, aquaculture, beef, swine, and poultry. The company’s products help treat, control, and prevent diseases, support nutrition, and aid in enhancing animal health & well-being. Its animal health products include vaccines, nutritional specialty products, anticoccidials, and antibacterial. It operates in Africa, Europe, Asia-Pacific, Latin America, and North America, with headquarters in Teaneck, the US.

Moreover, its product portfolio includes MB-1TM, a live vaccine for preventing infectious bursal disease in the hatchery in poultry. Besides, the company’s core strength is its established marketing, distribution, and sales network in more than 80 countries that facilitate global growth opportunities.

Report Synopsis

Report Scope	Details
Market Forecast Years	2022-2028
Base Year	2021
Market Historical Years	2018-2021
Forecast Units	Revenue (Million)
Segments Analyzed	Product Type, Animal Type, Disease Type
Companies Analyzed	Zoetis, Elanco Animal Health, Merck Animal Health, Phibro Animal Health, Neogen

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

RESEARCH SCOPE & METHODOLOGY
- STUDY OBJECTIVES
- SCOPE OF STUDY
- METHODOLOGY
- ASSUMPTIONS & LIMITATIONS
EXECUTIVE SUMMARY
- MARKET SIZE & ESTIMATES
- COUNTRY SNAPSHOT
- COUNTRY ANALYSIS
- KEY GROWTH ENABLERS
- KEY CHALLENGES
KEY ANALYTICS
- IMPACT OF COVID-19 ON VETERINARY VACCINES MARKET
- KEY MARKET TRENDS
- PORTER’S FIVE FORCES ANALYSIS
  - BUYERS POWER
  - SUPPLIERS POWER
  - SUBSTITUTION
  - NEW ENTRANTS
  - INDUSTRY RIVALRY
- VALUE CHAIN ANALYSIS
- KEY BUYING CRITERIA
- REGULATORY FRAMEWORK
MARKET BY ANIMAL TYPE
- LIVESTOCK ANIMAL
  - CATTLE
  - PIGS
  - POULTRY
  - SHEEP
  - OTHER LIVESTOCK ANIMALS
- COMPANION ANIMAL
  - CANINE
  - FELINE
  - EQUINE
- AQUACULTURE
MARKET BY PRODUCT TYPE
- ATTENUATED VACCINES
- INACTIVATED VACCINES
- TOXOID VACCINES
- CONJUGATE VACCINES
- DNA VACCINES
- RECOMBINANT VACCINES
- SUBUNIT VACCINES
MARKET BY DISEASE TYPE
- CANINE DISEASE
- PORCINE DISEASE
- BOVINE DISEASE
- POULTRY DISEASE
- AQUACULTURE DISEASE
- OTHER DISEASES
COMPETITIVE LANDSCAPE
- KEY STRATEGIC DEVELOPMENTS
  - MERGERS & ACQUISITIONS
  - PRODUCT LAUNCHES & DEVELOPMENTS
  - PARTNERSHIPS & AGREEMENTS
  - BUSINESS EXPANSIONS & DIVESTITURES
- COMPANY PROFILES
  - ELANCO ANIMAL HEALTH
  - MERCK ANIMAL HEALTH
  - NEOGEN
  - PHIBRO ANIMAL HEALTH
  - ZOETIS

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT – VETERINARY VACCINES

TABLE 2: REGULATORY FRAMEWORK

TABLE 3: UNITED STATES VETERINARY VACCINES MARKET, BY ANIMAL TYPE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 4: UNITED STATES VETERINARY VACCINES MARKET, BY ANIMAL TYPE, FORECAST YEARS, 2022-2028 (IN $ MILLION)

TABLE 5: UNITED STATES VETERINARY VACCINES MARKET, BY LIVESTOCK ANIMAL, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 6: UNITED STATES VETERINARY VACCINES MARKET, BY LIVESTOCK ANIMAL, FORECAST YEARS, 2022-2028 (IN $ MILLION)

TABLE 7: UNITED STATES VETERINARY VACCINES MARKET, BY COMPANION ANIMAL TYPE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 8: UNITED STATES VETERINARY VACCINES MARKET, BY COMPANION ANIMAL TYPE, FORECAST YEARS, 2022-2028 (IN $ MILLION)

TABLE 9: UNITED STATES VETERINARY VACCINES MARKET, BY PRODUCT TYPE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 10: UNITED STATES VETERINARY VACCINES MARKET, BY PRODUCT TYPE, FORECAST YEARS, 2022-2028 (IN $ MILLION)

TABLE 11: UNITED STATES VETERINARY VACCINES MARKET, BY DISEASE TYPE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 12: UNITED STATES VETERINARY VACCINES MARKET, BY DISEASE TYPE, FORECAST YEARS, 2022-2028 (IN $ MILLION)

TABLE 13: LEADING PLAYERS OPERATING IN UNITED STATES VETERINARY VACCINES MARKET

TABLE 14: LIST OF MERGERS & ACQUISITIONS

TABLE 15: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS

TABLE 16: LIST OF PARTNERSHIPS & AGREEMENTS

TABLE 17: LIST OF BUSINESS EXPANSIONS & DIVESTITURES

LIST OF FIGURES

FIGURE 1: KEY MARKET TRENDS

FIGURE 2: PORTER’S FIVE FORCES ANALYSIS

FIGURE 3: VALUE CHAIN ANALYSIS

FIGURE 4: KEY BUYING CRITERIA

FIGURE 5: UNITED STATES VETERINARY VACCINES MARKET, GROWTH POTENTIAL, BY ANIMAL TYPE, IN 2021

FIGURE 6: UNITED STATES VETERINARY VACCINES MARKET, BY LIVESTOCK ANIMAL, 2022-2028 (IN $ MILLION)

FIGURE 7: UNITED STATES VETERINARY VACCINES MARKET, GROWTH POTENTIAL, BY LIVESTOCK ANIMAL, IN 2021

FIGURE 8: UNITED STATES VETERINARY VACCINES MARKET, BY CATTLE, 2022-2028 (IN $ MILLION)

FIGURE 9: UNITED STATES VETERINARY VACCINES MARKET, BY PIGS, 2022-2028 (IN $ MILLION)

FIGURE 10: UNITED STATES VETERINARY VACCINES MARKET, BY POULTRY, 2022-2028 (IN $ MILLION)

FIGURE 11: UNITED STATES VETERINARY VACCINES MARKET, BY SHEEP, 2022-2028 (IN $ MILLION)

FIGURE 12: UNITED STATES VETERINARY VACCINES MARKET, BY OTHER LIVESTOCK ANIMALS, 2022-2028 (IN $ MILLION)

FIGURE 13: UNITED STATES VETERINARY VACCINES MARKET, BY COMPANION ANIMAL, 2022-2028 (IN $ MILLION)

FIGURE 14: UNITED STATES VETERINARY VACCINES MARKET, GROWTH POTENTIAL, BY COMPANION ANIMAL TYPE, IN 2021

FIGURE 15: UNITED STATES VETERINARY VACCINES MARKET, BY CANINE, 2022-2028 (IN $ MILLION)

FIGURE 16: UNITED STATES VETERINARY VACCINES MARKET, BY FELINE, 2022-2028 (IN $ MILLION)

FIGURE 17: UNITED STATES VETERINARY VACCINES MARKET, BY EQUINE, 2022-2028 (IN $ MILLION)

FIGURE 18: UNITED STATES VETERINARY VACCINES MARKET, BY AQUACULTURE, 2022-2028 (IN $ MILLION)

FIGURE 19: UNITED STATES VETERINARY VACCINES MARKET, GROWTH POTENTIAL, BY PRODUCT TYPE, IN 2021

FIGURE 20: UNITED STATES VETERINARY VACCINES MARKET, BY ATTENUATED VACCINES, 2022-2028 (IN $ MILLION)

FIGURE 21: UNITED STATES VETERINARY VACCINES MARKET, BY INACTIVATED VACCINES, 2022-2028 (IN $ MILLION)

FIGURE 22: UNITED STATES VETERINARY VACCINES MARKET, BY TOXOID VACCINES, 2022-2028 (IN $ MILLION)

FIGURE 23: UNITED STATES VETERINARY VACCINES MARKET, BY CONJUGATE VACCINES, 2022-2028 (IN $ MILLION)

FIGURE 24: UNITED STATES VETERINARY VACCINES MARKET, BY DNA VACCINES, 2022-2028 (IN $ MILLION)

FIGURE 25: UNITED STATES VETERINARY VACCINES MARKET, BY RECOMBINANT VACCINES, 2022-2028 (IN $ MILLION)

FIGURE 26: UNITED STATES VETERINARY VACCINES MARKET, BY SUBUNIT VACCINES, 2022-2028 (IN $ MILLION)

FIGURE 27: UNITED STATES VETERINARY VACCINES MARKET, GROWTH POTENTIAL, BY DISEASE TYPE, IN 2021

FIGURE 28: UNITED STATES VETERINARY VACCINES MARKET, BY CANINE DISEASE, 2022-2028 (IN $ MILLION)

FIGURE 29: UNITED STATES VETERINARY VACCINES MARKET, BY PORCINE DISEASE, 2022-2028 (IN $ MILLION)

FIGURE 30: UNITED STATES VETERINARY VACCINES MARKET, BY BOVINE DISEASE, 2022-2028 (IN $ MILLION)

FIGURE 31: UNITED STATES VETERINARY VACCINES MARKET, BY POULTRY DISEASE, 2022-2028 (IN $ MILLION)

FIGURE 32: UNITED STATES VETERINARY VACCINES MARKET, BY AQUACULTURE DISEASE, 2022-2028 (IN $ MILLION)

FIGURE 33: UNITED STATES VETERINARY VACCINES MARKET, BY OTHER DISEASES, 2022-2028 (IN $ MILLION)

SEGMENTATION

MARKET BY ANIMAL TYPE
- LIVESTOCK ANIMAL
  - CATTLE
  - PIGS
  - POULTRY
  - SHEEP
  - OTHER LIVESTOCK ANIMALS
- COMPANION ANIMAL
  - CANINE
  - FELINE
  - EQUINE
- AQUACULTURE
MARKET BY PRODUCT TYPE
- ATTENUATED VACCINES
- INACTIVATED VACCINES
- TOXOID VACCINES
- CONJUGATE VACCINES
- DNA VACCINES
- RECOMBINANT VACCINES
- SUBUNIT VACCINES
MARKET BY DISEASE TYPE
- CANINE DISEASE
- PORCINE DISEASE
- BOVINE DISEASE
- POULTRY DISEASE
- AQUACULTURE DISEASE
- OTHER DISEASES